Congratulations are in order for AngelMD portfolio company Artoss, Inc. Artoss is a medical device company that has developed NanoBone, an advanced synthetic bone graft technology.
NanoBone was tested alone (without addition of autograft or bone marrow aspirate) in the ASTM International standardized animal model and found to be equivalent to the “gold standard” autograft in fusion rate.
James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “The ASTM standard animal model for lumbar intertransverse process spinal fusion is a very challenging model designed to replicate clinically relevant fusion rates for iliac crest autograft in the posterolateral spine.
A majority of bone void fillers must be mixed with autograft in order to achieve equivalent fusion rates to autograft alone. We’re pleased to offer surgeons a synthetic alternative to autograft that does not require mixing with autograft or bone marrow. Using a synthetic bone void filler alone offers significant cost savings to hospitals. NanoBone stands alone.”
“NanoBone Bone Graft used as a standalone in posterolateral spinal fusion represents asignificant advancement in patient care.” said J. Eric Gee, M.D. “Eliminating the need to mix synthetic graft with autograft or to harvest and concentrate bone marrow aspirate will save time and money as well as streamline operating room procedures.”
NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.
Find the best in healthcare innovation. Join AngelMD today.
Image Credit: AngelMD